for Novel siRNA Therapeutics
James A. Mixson, M.D.
Dr. Mixson is a Scientific Founder of Sirnaomics and Professor at the University of Maryland. He is an expert in cancer, polymer design and drug delivery. He spearheaded the HK (histidine-lysine) polymer nanoparticle technology for siRNA delivery in vitro and in vivo which is now demonstrating tremendous potential in delivery of RNAi therapeutics. Dr. Mixson’s laboratory is developing novel gene targeting approaches for treating cancer. He received his B.A. from Vanderbilt University, and his M.D. degree from Emory University.
Xiaochang (Don) Dai, Ph.D.
Dr. Dai received his Ph.D. in Chemistry from The Scripps Research Institute, followed by postdoctoral studies at California Institute of Technology. He then became an entrepreneur founding and supporting successful companies in China, including KBN, a JV by TEVA, then KPC, a public company recognized for being the first to bring Nobel Prize winning discovery Artemisinin to commercialization. Dr. Dai brings a high level of entrepreneurial energy and acumen, combined with deep understanding of the company's underlying science and technology.